Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(NY:
MAIA
)
2.980
-0.020 (-0.67%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MAIA
< Previous
1
2
3
Next >
MAIA Biotechnology Announces No Exposure to Silicon Valley Bank
March 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment
March 07, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition
February 13, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
Sidoti's January Micro-Cap Conference
January 17, 2023
Via
ACCESSWIRE
MAIA Biotechnology Advances New Telomere-Targeting Molecule Program
January 17, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Participate in Four Upcoming Investor Conferences
January 05, 2023
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
December 20, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe
December 13, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan
November 22, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma
November 15, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
Sidoti's November Micro-Cap Virtual Conference
November 08, 2022
Via
ACCESSWIRE
MAIA Biotechnology to Participate in ThinkEquity Conference
October 06, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
September 29, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022
September 06, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids
August 30, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 22, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Receives FDA Orphan Drug Designation for THIO for the Treatment of Small-Cell Lung Cancer (SCLC)
August 02, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
MAIA Biotechnology Announces Closing of Initial Public Offering
August 01, 2022
From
MAIA Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.